Collaboration will initially accelerate C4X Discovery’s Parkinson’s disease drug discovery pipeline
Cambridge, UK, 25 June, 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announced they have signed a neurodegeneration drug discovery collaboration agreement. Combining the two companies’ technology platforms to validate novel targets, the initial focus will be on Parkinson’s disease.